The ARL1 Knockout A-549 Polyclonal Cells product consists of a heterogeneous population of CRISPR/Cas9-edited A-549 cells carrying targeted disruption of the ARL1 gene, which encodes a critical Golgi-associated small GTPase. This polyclonal knockout cell pool provides a loss-of-function model suitable for functional screening and pathway analysis, avoiding the clonal artifacts inherent in single-cell-derived lines. The heterogeneous editing profile mimics genetic diversity and allows robust phenotypic evaluation across a cell population.
The parental A-549 cell line is a well-characterized epithelial model derived from a lung adenocarcinoma of a 58-year-old Caucasian male. These cells retain features of human alveolar type II epithelium and are extensively utilized in lung cancer research, including studies of oncogenic transformation, metastatic progression, and drug resistance mechanisms.
ARL1 functions as a molecular switch at the trans-Golgi network, cycling between GDP-bound inactive and GTP-bound active states. Activation is facilitated by guanine nucleotide exchange factors BIG1 and BIG2, leading to recruitment of downstream effectors such as golgin-97 and golgin-245. These tethering proteins mediate COPI vesicle transport, cisternal stacking, and retrograde trafficking, maintaining Golgi architecture. ARL1 also interacts with GRIP domain-containing proteins, SCOCO, Arfaptin-2, and COPI coatomer subunits, while GTPase-activating proteins GIT1 and GIT2 promote its inactivation. Dysregulation of this network can impair secretory pathways and alter surface receptor expression, contributing to tumor progression.
In the A-549 lung adenocarcinoma context, ARL1 knockout enables dissection of Golgi-dependent processes shaping cancer cell behavior. Disruption of ARL1-mediated trafficking can attenuate secretion of matrix metalloproteinases and growth factors, potentially reducing invasive and metastatic capacity. Furthermore, altered receptor presentation due to Golgi dysfunction may modulate sensitivity to chemotherapeutic agents, making this model a valuable tool for drug resistance studies. The polyclonal format captures a range of knockout efficiencies, reflecting the heterogeneity of tumor cell populations.
This product supports diverse applications, including high-resolution immunofluorescence imaging of Golgi morphology using markers like GM130 and golgin-97, secretion assays to quantify cargo transport, and co-immunoprecipitation of ARL1 interactors such as golgin-245. Migration, invasion, and cell viability assays facilitate functional characterization, while RT-qPCR enables transcriptomic profiling of downstream targets. The cells are also compatible with pooled CRISPR screens and drug sensitivity analyses. For further information or technical inquiries, please contact Ascent Research.
